Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

Abstract Background Myelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction ≥50% from baseline. However, this dich...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruben A. Mesa, Stacie Hudgens, Lysbeth Floden, Claire N. Harrison, Jeanne Palmer, Vikas Gupta, Donal P. McLornan, Mary F. McMullin, Jean‐Jaques Kiladjian, Lynda Foltz, Uwe Platzbecker, M. Laura Fox, Adam J. Mead, David M. Ross, Stephen T. Oh, Andrew Perkins, Michael F. Leahy, Samineh Deheshi, Rafe Donahue, Barbara J. Klencke, Srdan Verstovsek
Formato: Artículo
Lenguaje:English
Publicado: Wiley 2023-05-01
Colección:Cancer Medicine
Materias:
JAK inhibitor
momelotinib
myelofibrosis
patient‐reported outcomes
symptoms
Acceso en línea:https://doi.org/10.1002/cam4.5799

Internet

https://doi.org/10.1002/cam4.5799

Ejemplares similares